Gene · 2248
Papers2,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 2,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Analysis on the desert adaptability of indigenous sheep in the southern edge of Taklimakan Desert. | Sci Rep | 2022 | 35851076 | PubTator, text mining | PubMed |
| Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis. | EJHaem | 2022 | 35846205 | PubTator, text mining | PubMed |
| CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. | Front Immunol | 2022 | 35844619 | PubTator, text mining | PubMed |
| Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B. | World J Urol | 2022 | 35841413 | PubTator, text mining | PubMed |
| Biocatalytic Intramolecular C-H aminations via Engineered Heme Proteins: Full Reaction Pathways and Axial Ligand Effects. | Chemistry | 2022 | 35840505 | PubTator, text mining | PubMed |
| Fibroblast growth factor receptor 1-bound extracellular vesicle as novel therapy for osteoarthritis. | Biomedicine (Taipei) | 2022 | 35836973 | PubTator, text mining | PubMed |
| LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC. | Front Pharmacol | 2022 | 35814257 | PubTator, text mining | PubMed |
| Dissecting Immunosuppressive Cell Communication Patterns Reveals JunB Proto-Oncogene (JUNB) Shaping a Non-Inflamed Tumor Microenvironment. | Front Genet | 2022 | 35812726 | PubTator, text mining | PubMed |
| Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. | J Hematol Oncol | 2022 | 35799264 | PubTator, text mining | PubMed |
| The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. | Gastric Cancer | 2022 | 35778636 | PubTator, text mining | PubMed |
| Role of Primary Cilia in Skeletal Disorders. | Stem Cells Int | 2022 | 35761830 | PubTator, text mining | PubMed |
| Thymus Functionality Needs More Than a Few TECs. | Front Immunol | 2022 | 35757725 | PubTator, text mining | PubMed |
| Magnesium-stabilised transition metal formyl complexes: structures, bonding, and ethenediolate formation. | Chem Sci | 2022 | 35756511 | PubTator, text mining | PubMed |
| Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup. | Life (Basel) | 2022 | 35743843 | PubTator, text mining | PubMed |
| Self-Organization of the Retina during Eye Development, Retinal Regeneration In Vivo, and in Retinal 3D Organoids In Vitro. | Biomedicines | 2022 | 35740479 | PubTator, text mining | PubMed |
| The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease. | Mol Oncol | 2022 | 35726685 | PubTator, text mining | PubMed |
| Enantioselective Cu-catalyzed double hydroboration of alkynes to access chiral gem-diborylalkanes. | Nat Commun | 2022 | 35725731 | PubTator, text mining | PubMed |
| Fibroblast Growth Factor 3 Is Associated with Tongue Squamous Cell Carcinoma: A Controlled Study. | Comput Math Methods Med | 2022 | 35720042 | PubTator, text mining | PubMed |
| Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 | 35705558 | PubTator, text mining | PubMed |
| The advanced development of molecular targeted therapy for hepatocellular carcinoma. | Cancer Biol Med | 2022 | 35699406 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2248/papers?page=21